Company Description
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.
The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain.
It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer.
Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others.
The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015.
Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
| Country | NY |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Denis D. Corin |
Contact Details
Address: 366 Madison Ave., 3rd Floor New York, New York 10017 United States | |
| Phone | 212-588-0022 |
| Website | qbiomed.com |
Stock Details
| Ticker Symbol | QBIO |
| Exchange | OTCMKTS |
| Fiscal Year | December - November |
| Reporting Currency | USD |
| CIK Code | 0001596062 |
| CUSIP Number | 74736N105 |
| ISIN Number | US74736N1054 |
| Employer ID | 46-4013793 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Denis D. Corin | Chairman, Chief Executive Officer and President |
| William S. Rosenstadt | Chief Legal Officer, General Counsel and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2023 | 10-Q/A | [Amend] Quarterly report |
| Jun 16, 2023 | 8-K | Current Report |
| Jun 16, 2023 | 10-Q | Quarterly Report |
| May 26, 2023 | 8-K | Current Report |
| May 26, 2023 | 10-K | Annual Report |
| Mar 1, 2023 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Jan 3, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 7, 2022 | DEF 14C | Filing |
| Nov 18, 2022 | 8-K | Current Report |
| Nov 18, 2022 | PRE 14C | Filing |